Glofitamab in Chinese Patients With R/R DLBCL
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorPeking Union Medical College Hospital
About this trial
This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.
Eligibility criteria
Qualifiers
Histologically-confirmed DLBCL
Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy
Participants must have measurable disease
Disqualifiers
Pregnancy or breastfeeding
Patient with known active infection, or reactivation of a latent infection
Patient with active autoimmune disease or immune deficiency
severe organ failure：LVEF<40%；DLCO<40%；eGFR<30ml/min；Bilirubin≥3ULN
Trial design
Treatments tested in this trial
- Glofitamab
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov